Renovaro BioSciences (NASDAQ: RENB), an advanced, preclinical biotechnology company, and GEDi Cube Intl Ltd., an AI medical technology company, previously announced a definitive agreement to combine. The move brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights and targeted immunotherapies. “According to CEO Dr. Mark Dybul, MD, the AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the precision medicine market, which Renovaro is positioned to capture a substantial share of the largely untapped market. The immunotherapy division plans to start Phase 1/2 trials of its lead asset in the second half of 2024, a breakthrough approach Dr. Dybul believes could lead to emergency use authorization as soon as the end of 2027 – following the results of a Phase 2 clinical trial that will transform treatment for cancers with low survival rates, like pancreatic cancer,” reads a recent article. “We believe GEDiCube’s AI technology will enhance and accelerate the development of treatments we are currently pursuing as well as power the discovery of new therapeutic approaches for cancer and other diseases,” Dr. Dybul is quoted as saying.
To view the full article, visit https://ibn.fm/cMKtu
About Renovaro BioSciences Inc.
Renovaro has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information on Renovaro, visit the company’s website at www.Renovarobio.com.
NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN